Vicarious Surgical officially shutting down

Vicarious Surgical investors voted on July 21, 2026, to immediately shut down and liquidate the soft-tissue surgical robotics developer. The board had unanimously proposed the move, saying the company could not predict whether proceeds would remain for investors after obligations. An assignee will liquidate its assets, while medical device OEMs that signed non-disclosure agreements can access its data room as assets are auctioned off.

Chief executive Stephen From, who joined in 2025, said he had discussed a possible sale with a buyer in recent days, but no deal resulted. He and all remaining employees lost their jobs on the closure date. The company had raised about $300 million, largely through a 2021 SPAC merger, but it could not bring its research and development program to a design freeze. From had hoped to reach that milestone by the end of 2026.

When From arrived in August 2025, annual spending was about $50 million. Restructuring reduced the burn rate below $20 million by the beginning of 2026, without changing the design-freeze target. However, a decline in market capitalization put the company on the NYSE watch list for possible delisting, undermining fundraising. From said the company believed an additional net $10 million could have carried it to year-end.

As of March 31, Vicarious reported nearly $3.7 million in cash, cash equivalents, and short-term investments, alongside $9 million in liabilities and $12.6 million in assets. It reported a $7.3 million quarterly loss, after losses of $50.2 million in 2025 and $63 million the preceding year. On March 9, it had 26 employees: 11 in R&D, regulatory, and clinical roles; eight in manufacturing and quality assurance; and seven in marketing, sales, and administration. The company leases 42,000 square feet of office space at its Waltham, Massachusetts, headquarters. CFO Sarah Romano has resigned to become CFO of SS Innovations on Aug. 3.